The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...
"GMA" shares an exclusive look inside the lab of the maker of such drugs as Mounjaro and Zepbound to show what it's doing to ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...
Eli Lilly & Co.'s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
The drug, called Mounjaro in the UK and Zepbound in the U.S., would be initially offered to obese people with at least three ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback